Patent Owner Granted Leave in IPR to Seek Correction of Claims Held Indefinite in Parallel District Court Litigation

Jan 29, 2021

Reading Time : 2 min

The petitioner in this case sought IPR of some, but not all, claims of the patent under review. After considering the patent owner’s preliminary response, the board instituted trial. Soon after institution, the patent owner filed its motion seeking leave to petition the Director for a certificate of correction related to certain claims not under review in the IPR. According to the patent owner, those claims included a mistake correctable under § 255. The petitioner filed an opposition and the patent owner subsequently filed a reply.

In analyzing the patent owner’s motion, the board explained that the Federal Circuit in Honeywell Int’l Inc. v. Arkema Inc., 939 F.3d 1345, 1349–50 (Fed. Cir. 2019) describes the three steps a patent owner must take when seeking a certificate of correction of a patent undergoing an IPR—namely: (1) seek authorization from the board to file a motion for leave; (2) if the board grants authorization, the patent owner must ask the board to cede its exclusive jurisdiction so that the patent owner can request a certificate of correction from the Director; and (3) if the board cedes its jurisdiction, the patent owner can then petition the Director for a certificate of correction.

In resolving the patent owner’s motion, the board explained that it did not have the authority to decide whether the patent owner met the requirements of § 255. Instead, according to the board, it could determine only whether the patent owner had provided enough basis to support its position that the mistake may be correctable by the Patent Office.

The board explained that § 255 states that the director may correct “a mistake of a clerical or typographical nature, or of minor character,” which “appears in a patent and a showing has been made that such mistake occurred in good faith.” The patent owner contended that the claims for which it sought correction contained such a mistake because they contained words such as “absorption bands,” which made no sense in the context of the patent, instead of the correct terminology, “diffraction peaks.” Although the patent owner acknowledged that the claims for which it sought correction were held indefinite—by a district court in a related litigation—they were correctable through a certificate of correction. The patent owner argued that Federal Circuit precedent made clear that the Patent Office has broader authority than a district court to correct errors in a patent. In granting the motion for leave, the board ordered the patent owner to submit, along with its request for a certificate of correction to the Patent Office, the full briefing before the board as well as the board’s decision.

Practice Tip: Patent owners facing a district court holding of indefiniteness should recognize that, under certain circumstances, they may seek a certificate of correction from the Patent Office, even if the patent is under review before the board. Critically, a patent owner facing such a situation must follow the proper procedural channels before the board to maximize its chances of success.

Mylan Pharms. Inc. et al. v. Merch Sharp & Dohme Corp., IPR2020-00040, Paper 76 (PTAB Dec. 23, 2020)

 

Share This Insight

Previous Entries

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

IP Newsflash

September 24, 2025

The Federal Circuit reversed a district court’s denial of judgment as a matter of law on non-infringement, thereby setting aside a $106 million jury verdict, after holding that prosecution history estoppel barred the patentee from asserting infringement under the doctrine of equivalents.

...

Read More

IP Newsflash

September 17, 2025

A magistrate judge in the District of Delaware issued a Report and Recommendation, that found the sole asserted claim was a “single means” claim and therefore invalid for lack of enablement. In reaching that conclusion, the magistrate judge rejected the patentee’s argument that the preamble of the claim disclosed a second element that satisfied the combination requirement of Section 112, paragraph 6 because the preamble simply recited a descriptor of the very apparatus that was the subject of the means-plus-function limitation in the body of the claim. The district court judge presiding over this case has scheduled a hearing to review the magistrate’s ruling.

...

Read More

IP Newsflash

September 9, 2025

The Federal Circuit has affirmed the PTAB’s determination that a patent challenger did not show the challenged claims were unpatentable for obviousness. The Federal Circuit concluded that substantial evidence, which included expert testimony, showed there was no motivation to combine the references.

...

Read More

IP Newsflash

August 29, 2025

In a recent order addressing four IPR proceedings, the PTAB exercised its inherent authority under 37 C.F.R. § 42.5(a) to sua sponte authorize post-hearing discovery on a potentially dispositive privity issue. The order followed a Director review decision that vacated and remanded earlier IPRs involving the same parties, patent family, and privity issue. 

...

Read More

IP Newsflash

August 29, 2025

The Patent Trial and Appeal Board denied institution of an inter partes review petition in part because it determined that a patent reference was not prior art under the common ownership exception of pre-AIA 35 U.S.C. § 103(c)(1).

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.